ORPHAZYME A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,090 DKK | 0.00% |
|
+4.11% | -18.05% |
| 03-27 | Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03-04 | FDA Extends Review of Zevra's Arimoclomol by Three Months | DJ |
Chart calendar Orphazyme A/S
ad45e38a0a916f10fc50d4.FXUbPJMgqDMNq-kGkCCCYc5XgeFyFgW1PMUp-zcPuUs.cy14CNlu3HlvypBK_nG6I7Qf574qSTPQTYtLzn9k2ARNJ2Fk10bgeUXgmg~3c686b5568577658cbd9f7555e58c1c3
Upcoming events on Orphazyme A/S
Past events on Orphazyme A/S
| 11/09/2023 | Q2 2023 Earnings Release |
| 17/05/2023 10:00 | Annual General Meeting |
| 25/04/2023 21:20 | Q4 2022 Earnings Release |
| 19/09/2022 | Interim 2022 Earnings Release |
| 29/06/2022 13:00 | Annual General Meeting |
| 07/06/2022 22:34 | FY 2021 Earnings Release |
| 30/05/2022 12:00 | Shareholders Meeting |
| 07/04/2022 10:00 | Shareholders Meeting |
| 15/02/2022 16:00 | Extraordinary Shareholders Meeting |
| 09/02/2022 | WORLD Symposium - Poster 236 |
| 08/02/2022 | WORLD Symposium - Poster 229 |
| 31/08/2021 13:00 | Interim 2021 Earnings Call |
| 31/08/2021 06:00 | Interim 2021 Earnings Release |
| 18/06/2021 13:00 | Niemann-Pick Disease Type C (NPC) FDA Approval Update Call - Second Call |
| 18/06/2021 07:00 | Niemann-Pick Disease Type C (NPC) FDA Approval Update Call - First Call |
| 11/05/2021 | European Network to Cure ALS Virtual Meeting |
| 29/04/2021 16:00 | B. Riley Neurosciences Conference |
| 28/04/2021 09:15 | Redeye Orphan Drugs Conference |
| 31/03/2021 | Guggenheim Healthcare Talks, Genomic Medicines & Rare Diseases Conference |
| 25/03/2021 16:00 | Annual General Meeting |
Annual results
| Fiscal Period | December | 2019 | 2020 |
|---|---|---|---|
|
Net sales Million DKK | Released Forecast Spread | 0,00 0,00 - | 0,00 1,91 - |
|
EBITDA Million DKK | Released Forecast Spread | -332 -333 0.1% | -603 -541 -11.44% |
|
EBIT Million DKK | Released Forecast Spread | -336 -335 -0.28% | -609 -567 -7.27% |
|
Earnings before Tax (EBT) Million DKK | Released Forecast Spread | -343 -339 -1.33% | -635 -477 -33.13% |
|
Net income Million DKK | Released Forecast Spread | -337 -336 -0.45% | -633 -498 -27.12% |
|
EPS DKK | Released Forecast Spread | -16 870 -15 115 -11.61% | -22 320 -12 893 -73.12% |
| Announcement Date | 28/02/20 | 02/03/21 |
Quarterly results
| Fiscal Period | December | 2019 S2 | 2020 S2 | 2021 S1 |
|---|---|---|---|---|
|
Net sales Million DKK | Released Forecast Spread | 0,00 | 0,00 0,00 - | 13,2 0,00 - |
|
EBITDA Million DKK | Released Forecast Spread | -171 -333 48.58% | ||
|
EBIT Million DKK | Released Forecast Spread | -171 -335 48.99% | -363 -400 9.16% | |
|
Earnings before Tax (EBT) Million DKK | Released Forecast Spread | -382 -400 4.46% | ||
|
Net income Million DKK | Released Forecast Spread | -174 -338 48.64% | -382 -400 4.45% | |
|
EPS DKK | Released Forecast Spread | -8 660 0,00 - | ||
| Announcement Date | 28/02/20 | 02/03/21 | 31/08/21 |
More events
Past sector events for Orphazyme A/S
- Stock Market
- Equities
- ORPHA Stock
- Calendar Orphazyme A/S
